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Abstract  43 
Antidepressant treatment for major depressive disorder remains suboptimal with response rates of just 44 
over 50%. Although treatment guidelines, algorithms and clinical keys are available to assist the clinician, 45 
the process of finding an effective pharmacotherapy to maximise benefit for the individual patient is largely 46 
by “trial and error” and remains challenging. This highlights a clear need to identify biomarkers of 47 
treatment response to help guide personalised treatment strategies. We have carried out the largest 48 
multiplex immunoassay based longitudinal study to date, examining up to 258 serum markers involved in 49 
immune, endocrine and metabolic processes as potential biomarkers associated with treatment response 50 
in 332 depression patients recruited from four independent clinical centres. We demonstrated for the first 51 
time that circulating Apolipoprotein A-IV, Endoglin, Intercellular Adhesion Molecule 1, Tissue Inhibitor of 52 
Metalloproteinases 1, Plasminogen Activator Inhibitor 1, Thrombopoietin, Complement C3, Hepatocyte 53 
Growth Factor and Insulin-like Growth Factor-Binding Protein 2 were associated with response to different 54 
antidepressants. In addition, we showed that specific sets of immune-endocrine proteins were associated 55 
with response to Venlafaxine (serotonin–norepinephrine reuptake inhibitor), Imipramine (tricyclic 56 
antidepressant) and other antidepressant drugs. However, we were not able to reproduce the literature 57 
findings on BDNF and TNF-, two of the most commonly reported candidate treatment response markers. 58 
Despite the need for extensive validation studies, our preliminary findings suggest that a pre-treatment 59 
immune-endocrine profile may help to determine a patient’s likelihood to respond to specific 60 
antidepressant and/or alternative treatments such as anti-inflammatory drugs, providing hope for future 61 
personalised treatment approaches.  62 
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Introduction  82 
Antidepressant drugs are currently the mainstay of treatment for major depressive disorder (MDD). 83 
However, their effectiveness is suboptimal and highly variable due to disease heterogeneity and individual 84 
differences in drug metabolism, pharmacokinetics and toxicity (Miller and O'Callaghan, 2013). Although 85 
treatment guidelines (Maudsley (Taylor et al., 2015), NICE (NICE, 2010)), algorithms (Texas Medication 86 
Algorithm) (Suehs BT AT et al., 2008)) and clinical keys are available to assist the clinician to optimise 87 
outcome and reduce side-effects of treatment, the process of finding an effective pharmacotherapy 88 
to maximise benefit for the individual patient is largely by “trial and error” and remains challenging.  89 
Typically, it takes at least four weeks for an initial response to be observed and six to 12 weeks or more to 90 
attain remission with an initial antidepressant drug prescribed at an adequate dose (Rush et al., 2009). 91 
While response rates are on average 53.8% (37.3% for placebo response) (Papakostas and Fava, 2009), 92 
patients need to remain on an initially prescribed medication for many weeks to determine whether it will 93 
be effective. The non-responders are then prescribed another drug of the same or a different class, 94 
medication doses are adjusted and/or combinations are tested. This process may take many months until 95 
recovery is achieved (Keitner et al., 1992) and, many patients experience difficulty with side effects 96 
including weight gain, anxiety, decrease in libido and gastrointestinal symptoms. Crucially, the consequence 97 
of a lengthy treatment process is lack of medication compliance, which can result in poor treatment 98 
response. Large studies have shown that medication compliance drops significantly with duration of 99 
treatment (Olfson et al., 2006). Lack of compliance and failure to respond to antidepressants contribute 100 
heavily towards reduction of quality of life and productivity. Healthcare costs are also increased along with 101 
the risk of relapse and suicide (Miller and O'Callaghan, 2013). 102 
As a result, the need to develop reliable treatment response predictors to guide personalised 103 
treatment strategies is becoming a pressing clinical need. Decades of research effort have now laid the 104 
foundation towards achieving this goal. Studies have consistently demonstrated molecular changes in both 105 
the central nervous system and the periphery in MDD patients (Chan et al., 2014; Kaestner et al., 2005), 106 
including alterations in the endocrine system involving the hypothalamic-pituitary-adrenal axis (HPA), 107 
carbohydrate/lipid metabolism and most prominently, the immune/inflammatory system. For instance, a 108 
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chronic low grade inflammatory response and activation of cell-mediated immunity is frequently observed 109 
in depression (Berk et al., 2013). Exogenous cytokine and endotoxin infusions have been found to induce 110 
depressive-like symptoms in some individuals (Udina et al., 2012). Antidepressant drugs have been shown 111 
to decrease production of pro-inflammatory cytokines and increase release of anti-inflammatory cytokines 112 
(Maes et al., 1999). Remission is often accompanied by a normalisation of inflammatory markers and non-113 
response, at least in some cases, is associated with persistently elevated levels of such biomarkers 114 
(Hannestad et al., 2011). Anti-inflammatory drugs have also been found to ameliorate depressive 115 
symptoms in MDD patients, but these drugs may only be effective in specific subgroups of patients 116 
(Hashimoto, 2015).  117 
The important question, which arises from these findings, is that it may be possible to sub-stratify 118 
patients based on their immune-endocrine profile. This differential profile could reflect the individual 119 
differences in efficacy and responses to antidepressant and/or anti-inflammatory drugs. Recently, a 120 
number of candidate treatment response predictors have been proposed including Brain-Derived 121 
Neurotrophic Factor (BDNF), Tumour Necrosis Factor Alpha (TNF-α), Interleukin-6 (IL-6), S100 calcium-122 
binding protein B (S100-B) (Abou-Saleh et al., 1998; Papakostas, 2012), C-Reactive Protein (CRP) (Uher et 123 
al., 2014), Macrophage Migration Inhibitory Factor (MIF), Interleukin-1-β (IL-1) (Cattaneo et al., 2016) and 124 
circulating leukocyte subpopulations (Grosse et al., 2016). Functional and structural brain imaging 125 
predictors have also been reported (Phillips et al., 2015). Studies examining pharmacological (drug-126 
metabolizing enzymes) and genomic predictors have also shown promise (Leuchter et al., 2009). 127 
Nevertheless, to date, the most reliable predictors identified have been the symptomatic and physiologic 128 
features of patients that emerge early in the course of treatment, which unfortunately still lack sensitivity 129 
and specificity. 130 
With this in mind, we carried out the largest multiplex immunoassay based study, to date, to 131 
identify candidate blood-based biomarkers of treatment response in serum from 332 MDD patients 132 
recruited from four independent clinical centres.  133 
 134 
 135 
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Materials and Methods 136 
Clinical cohorts 137 
MDD patients were recruited consecutively from four independent clinical centres. Cohorts 1 (n=30) and 2 138 
(n=26) were from the Department of Psychiatry of the Erasmus Medical Center (MC), the Netherlands. 139 
Cohort 3 (n=38) was from the Department of Psychiatry, University of Magdeburg, Germany. Cohort 4 140 
(n=21) was from the Department of Psychiatry, University of Muenster, Germany. Cohort 5 (n=217) 141 
consisted of a subset of the multi-site Netherlands Study of Depression and Anxiety (NESDA) cohort. 142 
Informed written consent was given by all participants. Study protocols, sample collection and analysis 143 
methods were approved by the respective institutional ethical committees and review boards and were in 144 
compliance with the Standards for Reporting of Diagnostic Accuracy (STARD) (Bossuyt et al., 2003). Patients 145 
from all cohorts were fasting at the time of blood collection. For cohorts 1-4, diagnosis was carried out 146 
using the Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR)(API, 2000). 147 
Depression symptom severity was determined using the Hamilton Rating Scale for Depression, 17-item-148 
version (HAMD) (Table 1).  149 
The Erasmus MC patients were from a double-blind randomised clinical trial aimed to compare the 150 
efficacy of a plasma level-targeted dose of imipramine (tricyclic antidepressant (TCA)) and high-dose 151 
venlafaxine (serotonin-norepinephrine reuptake inhibitor (SNRI)) in severely depressed inpatients. For the 152 
present study, a subset of 56 patients from the trial was included based on availability of baseline serum 153 
samples. All patients were antidepressant medication free for at least one week prior to baseline 154 
assessment. Following baseline assessment, 30 patients were initiated on treatment with Venlafaxine 155 
(doses increased gradually to 300–375 mg/day, cohort 1) and 26 patients were initiated on treatment with 156 
Imipramine (doses adjusted to a blood level of 200–300 ng/ml, cohort 2) for seven weeks. Note that 157 
patients from the venlafaxine and imipramine arms are referred as cohorts 1 and 2, respectively, 158 
throughout the text to facilitate description of results and discussion.   159 
Clinical assessments involved determination of psychiatric history, assessment of adequacy of 160 
treatment(s) in the current episode using the Antidepressant Treatment History Form, medical history and 161 
physical examination including vital signs and routine laboratory assessments. Exclusion criteria included 162 
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acute indication for electroconvulsive therapy (ECT), mental retardation, alcohol or substance dependence 163 
within three months of enrolment, any serious chronic somatic illnesses or medications affecting mood and 164 
contraindications for study medication. Notably, the percentage of patients from cohort 1 and 2 that took 165 
anxiolytics (mostly lorazepam before the night, all of which stayed under the predefined maximum dosage 166 
of lorazepam 3 mg) was 10%. The design of the main double-blind randomized clinical trial was previously 167 
described in detail (Vermeiden et al., 2013).  168 
The 38 patients from cohort 3 were either drug-naïve (n=27) or medication free for at least six 169 
weeks (n=11) prior to baseline assessment. All 21 patients from cohort 4 were medication free for at least 170 
one week prior to baseline interview. Following baseline assessment, patients from both cohorts 3 and 4 171 
were initiated on mixed antidepressant treatment (i.e. different antidepressant drugs administered either 172 
as monotherapy or combination therapy) for six and 4-26 weeks, respectively (Table 1). The choice of 173 
antidepressant medication regimen was based on psychiatrist’s clinical experience. Information on 174 
antidepressant medication use prior to hospitalisation was confirmed by direct contact with the treating 175 
family physicians and relatives. Exclusion criteria included pregnant women, infections, immune and 176 
autoimmune diseases, cancer or systemic diseases, cardiovascular disorders, diabetes, antibiotic and 177 
immune -suppressant/-modulatory treatment, substance abuse, alcohol or drug addiction, renal 178 
insufficiency, other neurologic or neuropsychiatric disorders and severe trauma. Exclusions were based on 179 
self-report, physician’s report or by physical examination.  180 
Cohort 5 was a subset of the NESDA cohort, an ongoing multi-site naturalistic longitudinal cohort 181 
study. This is a 2981 participant cohort (18–65 yrs), including 2329 individuals with lifetime or current 182 
anxiety and/or depressive disorders and 652 healthy controls. Participants were recruited from the general 183 
population, primary and specialised mental healthcare centres between 2004 and 2007. Exclusion criteria 184 
at baseline included lack of fluency in Dutch or another primary clinical psychiatric disorder (e.g. bipolar, 185 
psychotic, obsessive compulsive or severe addiction disorders). Details of the rationale, objectives and 186 
methods of this study are reported elsewhere (Penninx et al., 2008). Diagnoses of MDD were based on the 187 
Composite International Diagnostic Interview (CIDI), Lifetime Version 2.1 (WHO Lifetime Version 2.1), which 188 
establishes diagnoses according to DSM-IV criteria (Hardeveld et al., 2013). Depression severity was 189 
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determined using the 30-item Inventory of Depressive Symptoms Self-Report Questionnaire (IDS-SR30) 190 
(Rush et al., 1996). For the present study, we analysed 217 NESDA individuals with a current diagnosis of 191 
MDD (six-month recency) who initiated treatment with an antidepressant (could be from multiple classes) 192 
during the two year follow-up period and, who at year two (Ty2), were still on antidepressant use. Patients 193 
who had no overnight fast before baseline blood draw and women who were pregnant or over 32 days 194 
since last menstruation were not included in this sample. Patients that were on lengthy (over 2 months) 195 
antidepressant use already at baseline were also excluded in order to focus on persons who were 196 
antidepressant free or only recently initiated antidepressant use. 197 
 198 
Definitions of treatment response 199 
Treatment response was defined as at least 50% reduction in HAMD sum scores from baseline to endpoint 200 
(weeks 4-26) for cohorts 1-4 and, at least 50% reduction in IDS sum scores from baseline to endpoint (year 201 
two) for cohort 5. 202 
 203 
Serum preparation and multiplex immunoassay 204 
Standard operating protocols were followed for serum sample preparation across all clinical centres, as 205 
described previously (Chan et al., 2015b). The Multi-Analyte Profiling immunoassay platform 206 
(DiscoveryMAP) was used to measure the concentrations of 258 (cohort 1), 256 (cohort 2), 190 (cohort 3), 207 
147 (cohort 4) and 243 (cohort 5) proteins in patient sera. The number of proteins measured in each cohort 208 
was different because different upgrade versions of the DiscoveryMAP platforms were used over time, 209 
each measuring slightly different proteins. The proteins measured were mainly involved in 210 
immune/inflammatory, endocrine and metabolic processes previously implicated in several psychiatric 211 
disorders including depression (Bot et al., 2015; Chan et al., 2015b; Haenisch et al., 2014). All assays were 212 
conducted in the Clinical Laboratory Improved Amendments (CLIA)–certified laboratory at Myriad-RBM 213 
(Austin, TX, USA) (described previously (Chan et al., 2015b)). All serum samples were stored at -80°C until 214 
analysis.  215 
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 216 
Statistical analysis 217 
All statistical analyses were performed in R (http://www.R-project.org/) (RCoreTeam, 2013). Data from all 218 
cohorts were quality control (QC) assessed and pre-processed to exclude proteins with greater than 30% 219 
missing values (QC criteria), as described previously (Chan et al., 2015b). The remaining data with values 220 
below or above the detection limits were imputed by the minimum and maximum detected values, 221 
respectively. Data were log10-transformed to stabilise variance and approximate normality. Sample outliers 222 
were examined using principal components analysis (PCA) (Barnett and Lewis, 1978) and through inspection of 223 
quantile-quantile (Q-Q) plots. Linear regression analyses were carried out to identify biomarkers associated 224 
with treatment response. For each regression model, the pre-treatment protein levels were individually 225 
included as predictor variables and the absolute change in depression scores (absolute change in HAMD 226 
scores (∆HAMD) for cohorts 1-4 and IDS scores (∆IDS) for cohort 5) was modelled as the continuous 227 
outcome variable. This was done for each cohort. Covariate adjustment was accomplished through forward 228 
and backward stepwise regression, with selection based upon Bayesian Information Criterion (BIC). For 229 
cohorts 1-4, the clinical and sociodemographic covariates adjusted for included baseline HAMD scores, age, 230 
gender and BMI. For cohort 5, a larger set of sociodemographic covariates were available for adjustment 231 
including baseline IDS scores, age, gender, BMI, anxiety diagnosis comorbidity, chronic diseases and 232 
somatic medication (Table 1). Regression diagnostics were examined to ensure that all the model 233 
assumptions were met. False discovery rate was controlled according to Benjamini and Hochberg 234 
(Benjamini and Hochberg, 1995). However, given that this was an exploratory study, unadjusted P-values of 235 
less than 0.05 were considered to be worth further study. Biological and molecular functions were assigned 236 
using Swissprot (UniProt, 2015).  237 
 238 
 239 
 240 
 241 
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Results 242 
Patient characteristics and treatment response rates 243 
The baseline patient characteristics are described in Table 1. Briefly, patients from cohorts 1 and 2 were on 244 
average 10 years older than patients from cohorts 3-5. While cohort 1 had an equal proportion of male and 245 
female patients with an average BMI of 23, the remaining cohorts had more females (58-67%) and a higher 246 
BMI of 25-26. Contrary to cohorts 1-4, patients who were either drug-naive or antidepressant medication 247 
free for one or six weeks, approximately 79% of cohort 5 patients were receiving antidepressants at 248 
baseline for less than two months. In addition, unlike cohort 1-4 patients who were recruited from 249 
specialised mental healthcare, cohort 5 patients were from the general population (7%), primary care (26%) 250 
and specialised mental healthcare (67%). Finally, approximately 71% of patients from cohort 5 also had a 251 
comorbid anxiety diagnosis, which was not the case for cohorts 1-4. The treatment response rates varied 252 
across the cohorts. High response rates of over 84% to 4-26 weeks treatment with mixed antidepressants 253 
were observed for drug-naive or medication free patients from cohorts 3 and 4. While response to seven 254 
weeks of treatment with Venlafaxine (cohort 1) was 63%, treatment with Imipramine (cohort 2) only 255 
resulted in a 27% response. Similarly, longer-term treatment of up to two years with mixed antidepressants 256 
in cohort 5 also only resulted in a response rate of 29%.   257 
 258 
Multiplex immunoassay data QC and pre-processing 259 
Approximately 16-30% of proteins failed QC (i.e. >30% missing values) across the five cohorts. The number 260 
of proteins left for analysis in each cohort was 218 (cohort 1), 211 (cohort 2), 150 (cohort 3), 115 (cohort 4) 261 
and 171 (cohort 5) (Supplementary Table 1). In total, 78 (31%) proteins were measured in all five cohorts, 262 
54 (22%) in any four cohorts, 56 (23%) in any three cohorts, 31 (12%) in any two cohorts and 29 (12%) in 263 
only one cohort.  264 
 265 
 266 
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Biomarkers associated with antidepressant treatment response  267 
The biomarkers associated with antidepressant treatment response identified were predominantly involved 268 
in immune/inflammatory processes and blood coagulation followed by endocrine and growth factor 269 
signalling (Table 2 and Supplementary Table 2). A total of 11 baseline proteins were associated with 270 
response to Venlafaxine treatment (cohort 1). Of these, nine were negatively (-) associated with response 271 
(i.e. a lower pre-treatment protein level is associated with better response) and two were positively () 272 
associated with response (i.e. a higher pre-treatment protein level is associated with better response). 273 
Twenty-five proteins were associated with response to Imipramine (cohort 2) including 12 negative and 13 274 
positive associations. While 19 (four negative and 15 positive) proteins were associated with response to 275 
six weeks of treatment with mixed antidepressants (cohort 3), another 23 (10 negative and 13 positive) 276 
were associated with response to 4-26 weeks of treatment with mixed antidepressants (cohort 4). Tissue 277 
Inhibitor of Metalloproteinases 1 (TIMP-1) and Intercellular Adhesion Molecule 1 (ICAM-1) along with two 278 
acute phase proteins, Plasminogen Activator Inhibitor 1 (PAI-1) and Thrombopoietin (TPO), were the four 279 
biomarkers of treatment response in common between these two cohorts. Finally, a total of 12 proteins 280 
were associated with response to longer-term treatment of two years with mixed antidepressants in the 281 
naturalistic NESDA cohort 5, including nine negative and three positive associations. 282 
Notably, the proteins associated with response to the different antidepressant treatments across 283 
the various cohorts were largely different or potentially antidepressant specific with only nine proteins in 284 
common in at least two out of the five cohorts. These proteins included Apolipoprotein A-IV (ApoA-IV), 285 
Endoglin, ICAM-1, PAI-1, TIMP-1, TPO, Complement C3 (C3), Hepatocyte Growth Factor (HGF) and Insulin-286 
like Growth Factor-Binding Protein 2 (IGFBP-2) (Table 2). ApoA-IV was the most reproducible biomarker of 287 
treatment response as it was significantly associated with response to treatment in three out of five 288 
cohorts. Lower pre-treatment ApoA-IV levels were associated with better response to seven weeks of 289 
treatment with Venlafaxine (=-26.47, p=0.001) and six weeks with mixed antidepressants (cohort 3: =-290 
8.24, p=0.029) but poorer response to a longer-term treatment with mixed antidepressants in the 291 
naturalistic cohort 5 (=9.39, p=0.027) (Figure 1). Endoglin, also known as CD105, was another notable 292 
biomarker of treatment response. While it was only measured in three cohorts (1, 2 and 5), it associated 293 
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with response to treatment in all three cohorts. For instance, lower pre-treatment levels were associated 294 
with better response to treatment with Venlafaxine (=-22.61, p=0.035) and Imipramine (=-34.56, 295 
p=0.011), respectively, but poorer response to longer-term treatment with mixed antidepressants in cohort 296 
5 (=22.89, p=0.004). ICAM-1 was also associated with response to antidepressant treatment in three 297 
cohorts. Higher pre-treatment levels were associated with better response to mixed antidepressants in 298 
both cohorts 3 (=22.31, p=0.001) and 4 (=20.37, p=0.001) but poorer response to Venlafaxine treatment 299 
(=-21.08, p=0.035) (Figure 1). The remaining six proteins were also associated with response to several 300 
treatments. For example, higher pre-treatment levels of the three blood coagulation proteins, PAI-1, TIMP-301 
1 and TPO, were associated with better response to mixed antidepressant treatment in both cohorts 3 and 302 
4. On the other hand, the immune/inflammatory protein, C3, and the growth factor signalling proteins, HGF 303 
and IGFBP-2, were associated with response to Imipramine and mixed antidepressants (cohorts 3 or 4), 304 
inversely (Figure 1). 305 
 306 
Validation the ApoA-IV findings by liquid-chromatography mass spectrometry (LC–MSE) 307 
Of the nine candidate biomarkers of treatment response described above, two including ApoA-IV and 308 
Endoglin were not measured in cohort 4 due to use of an older version of the DiscoveryMAP. In order to 309 
validate these results, we examined LC–MSE data from an unpublished study measuring over 400 proteins 310 
in serum from 25 MDD patients (mean age (44 years) and gender (7 males, 18 females)). Seventeen of 311 
which were also part of our cohort 4. For details of the LC–MSE approach see Supplementary Material. We 312 
found that Endoglin was not measurable by LC–MSE but ApoA-IV was and its pre-treatment levels were 313 
indeed significantly associated with response to 4-26 weeks of mixed antidepressant treatment (=-15.60, 314 
p=0.034), validating the results from the other three cohorts (Figure 1).  315 
 316 
 317 
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Discussion 318 
Promising candidate biomarkers of treatment response have emerged from recent studies. In the present 319 
study, we extended these findings by profiling up to 258 pre-treatment immune/inflammatory, endocrine 320 
and metabolic serum proteins from 332 MDD patients recruited from multiple independent clinical centres.  321 
Firstly, we found that nine proteins, ApoA-IV, Endoglin, ICAM-1, PAI-1, TIMP-1, TPO, C3, HGF and 322 
IGFBP-2, were significantly associated with response to several antidepressants. Although validation is 323 
warranted, this finding supported a potential role of such biomarkers in treatment response. Equally, this 324 
finding also suggested a “generic” role of ApoA-IV in treatment response independent of drug or drug class 325 
(Figure 1 and Table 2). Secondly, we showed that a distinct and specific set of immune-endocrine proteins 326 
were significantly associated with response to certain classes of antidepressants or indeed specific 327 
antidepressant drugs. This implied that in the future it may be possible to match the appropriate 328 
medication to a given patient based on their pre-treatment immune-endocrine profile. The fact that most 329 
of the biomarkers of treatment response identified have previously been implicated in depression further 330 
reinforces their role in treatment response (Table 2 for supporting literature references). Importantly, 331 
despite the need for further validation, our findings may represent the first preliminary steps towards 332 
establishing robust treatment response predictors, providing hope for future personalised treatment 333 
approaches (Figure 1).  334 
The strength of our study was that we investigated patients (cohorts 1-4) who were free of major 335 
chronic illnesses and somatic medications as well as drug-naive or medication free prior to baseline 336 
assessment and blood collection. These factors typically affect blood protein levels and some of the chronic 337 
illnesses are known to be linked with a greater risk to develop depression (Haddad et al., 2015). Treatment 338 
with antidepressant monotherapies (Venlafaxine and Imipramine) was also a strength of this study, as it 339 
enables identification of drug-specific biomarkers of treatment response. In the naturalistic cohort 5, we 340 
also statistically adjusted for these confounding factors in our regression models. 341 
ApoA-IV is a circulating lipoprotein that regulates lipid absorption, transport and metabolism and, 342 
controls satiety (Stan et al., 2003). This protein has been reported to be increased in MDD (Bot et al., 2015) 343 
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and post-stroke depression patients (Zhan et al., 2014) and, has recently been included in a panel of 344 
biomarkers used to discriminate older adults with and without depressive symptoms (Arnold et al., 2012). 345 
Nevertheless, circulating ApoA-IV has not been previously associated with treatment response in MDD 346 
patients. We showed that patients with lower pre-treatment ApoA-IV levels responded better to treatment 347 
with Venlafaxine and mixed antidepressants in both cohorts 3 and 4. However, patients from the 348 
naturalistic NESDA cohort 5 with lower ApoA-IV levels had poorer responses to longer-term treatment of 349 
up to two years with mixed antidepressants. Note that there are fundamental differences between this and 350 
the shorter-term treatment cohorts 1-4. Given the naturalistic and non-interventional nature of cohort 5, 351 
medication compliance was not monitored during the two years of treatment and was only based on self-352 
reports; most patients had a comorbid anxiety diagnosis, which can affect treatment efficacy (Fava et al., 353 
2008); and, patients were not excluded on the basis of having comorbid chronic illnesses or taking somatic 354 
medications, although such variables were included as covariates in the backward and forward stepwise 355 
regression analysis.  356 
Endoglin is involved in vascular regulation and angiogenesis, induces inflammation and release of 357 
angiogenic factors from inflammatory cells (Nassiri et al., 2011). This protein has not been previously 358 
implicated in depression or associated with antidepressant treatment response. In our study, Endoglin was 359 
not measured in two cohorts but it was significantly associated with response to treatment in all the 360 
cohorts where it was measured. Patients with lower pre-treatment Endoglin levels responded better to 361 
both Venlafaxine and Imipramine monotherapies but had poorer responses to longer-term treatment with 362 
mixed antidepressants in the NESDA cohort.  363 
ICAM-1 is an immunoglobulin (Ig)-like cell-adhesion receptor that is involved in leukocyte adhesion 364 
and movement across the endothelium during inflammation. Expression is regulated by pro-inflammatory 365 
cytokines and stress (Mruk et al., 2014). ICAM-1 has been reported to be increased in both serum 366 
(Dimopoulos et al., 2006; Lesperance et al., 2004) and post-mortem brain tissue from depression patients 367 
(Thomas et al., 2000). We found that patients with higher pre-treatment ICAM-1 levels responded better to 368 
mixed antidepressants in cohorts 3 and 4 but had poorer responses to Venlafaxine treatment (Figure 1).  369 
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The remaining seven proteins that were associated with response to several antidepressants have 370 
all been previously implicated in depression. For example, the blood coagulation and positive acute phase 371 
(+AP) proteins, PAI-1, TIMP-1 and TPO have been shown to be increased in MDD patients (Domenici et al., 372 
2010; Eskandari et al., 2005; Gorska-Ciebiada et al., 2016; Tsai et al., 2008). Genetic variants of the PAI-1 373 
gene have been linked to depression as well as antidepressant treatment response (Tsai et al., 2008). In our 374 
study, patients from cohorts 3 and 4 with higher pre-treatment levels of these three proteins responded 375 
better to mixed antidepressants. The immune/inflammatory protein, C3 (+AP) along with the growth factor 376 
signalling proteins, HGF (+AP) and IGFBP-2, were all associated with response to Imipramine and either 377 
short or long-term treatment with mixed antidepressants. While C3 and IGFBP-2 have both been found to 378 
be increased in MDD (Domenici et al., 2010; Powell et al., 2014), HGF has been reported to be both 379 
decreased (Russo, 2010) and increased (Arnold et al., 2012) in patients.  380 
 381 
Limitations of the study 382 
The use of different versions of the multiplex immunoassay platform and difficulty to reliably measure over 383 
250 proteins covering a wide protein concentration range was a notable limitation of our study. Protein 384 
exclusion rate due to QC failure ranged between 16% and 30%. The overlap of proteins measured across all 385 
five cohorts was only 31%, followed by 22% in any four, 23% in any three and 12% in any two cohorts. This 386 
limitation directly compromises assessment of reproducibility of some of the candidate biomarkers of 387 
treatment response including, for example, Endoglin and some of the other biomarkers identified in only 388 
one cohort (Table 2). Also as a result, some of the previously reported treatment related proteins such as 389 
IL-6, S100-B, IL-1and IFN-(Janssen et al., 2010) could not be fully assessed. Consequently, future work 390 
attempting to improve consistency and reliability of protein measurement is warranted. On the other hand, 391 
we did reliably measure BDNF and TNF-, two of the most commonly studied candidate biomarkers of 392 
treatment response (Mikoteit et al., 2014; Papakostas, 2012), but were not able to reproduce the reported 393 
findings in our study. We also acknowledge the fact that despite promising, some of our findings were in 394 
opposite directions across cohorts and failed to project to the naturalistic cohort. For instance, while the 395 
ApoA-IV and Endoglin associations with treatment response were consistent across the smaller shorter-396 
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term treatment cohorts, the effects were in opposite direction in the larger naturalistic but fundamentally 397 
different longer-term treatment cohort 5. Similarly, opposite directions of association between ICAM-1, C3, 398 
HGF and IGFBP-2 and treatment response were observed across the venlafaxine or imipramine 399 
monotherapy cohorts (cohorts 1 and 2) and the mixed antidepressant treatment cohorts (cohorts 3 and 4). 400 
While these results could suggest that these proteins may play a role in treatment response depending on 401 
the class or specific antidepressant drug, the presence of inconsistencies across some of the key findings 402 
highlight the need for validation studies. The disagreement of results with the literature and importantly, 403 
within our own study may be explained by the heterogeneity of the patient population characterised by 404 
sociodemographic, lifestyle and clinical factors, disease comorbidities and concomitant medications. 405 
Differences in sample sizes and duration of treatment, variety of antidepressant medications administered, 406 
the heterogeneity of the concept “depression” and whether the original diagnosis of MDD was correct i.e. 407 
misdiagnosis of bipolar disorder in depressive phase, may also explain some of the inconsistencies, which 408 
altogether challenge the comparison of findings across cohorts. Finally, we acknowledge the fact that our 409 
findings are at very preliminary stages and are not immediately useful to every-day clinical practice. 410 
 411 
In summary, we demonstrated for the first time that circulating ApoA-IV, Endoglin, ICAM-1, PAI-1, TIMP-1, 412 
TPO, C3, HGF and IGFBP-2 were associated with response to some antidepressant drugs and, that specific 413 
sets of immune-endocrine proteins were associated with response to certain classes or individual 414 
antidepressant drugs. These preliminary findings may represent early steps towards future personalised 415 
treatment approaches. 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
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Tables  648 
Table 1. Patient clinical and sociodemographic characteristics at baseline  649 
a) 650 
 
Cohort 1 (n=30) Cohort 2 (n=26) Cohort 3 (n=38) Cohort 4 (n=21) 
Numerical variables (mean|median (SD) [min-max]) 
Age  54|58 (9) [34-67] 54|56 (11) [32-82] 43|45 (12) [19-59] 42|42 (12) [22-59] 
BMI (kg/m2) 23|23 (3) [15-31] 25|24 (4) [17-33] 26|25 (5) [16-43] NR 
HAMD score 24|24 (3) [18-31] 25|26 (3) [19-30] 22|22 (7) [9-37] 28|29 (5) [21-38] 
Follow-up HAMD score 11|10 (8) [1-34] 18|19 (9) [1-36] 7|8 (4) [0-18] 7|7 (3) [0-14] 
Categorical variables     
Follow-up time-point Week 7 Week 7 Week 6 Week 4-26 
Response (HAMD reduction ≥50%) by follow-up    
No 11 (37%) 19 (73%) 6 (16%) 1 (5%) 
Yes 19 (63%) 7 (27%) 32 (84%) 20 (95%) 
Gender     
Female 15 (50%) 17 (65%) 22 (58%) 14 (67%) 
Male 15 (50%) 9 (35%) 16 (42%) 7 (33%) 
Baseline antidepressant medication    
No* 30 (100%) 26 (100%) 38 (100%) 21 (100%) 
Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Follow-up antidepressant class     
No 0 (0%) 0 (0%) 2 (5%) 0 (0%) 
SNRI 30 (100%)# 0 (0%) 11 (29%) 6 (29%) 
TCA 0 (0%) 26 (100%)
†
 1 (3%) 1 (5%) 
NaSSA 0 (0%) 0 (0%) 8 (21%) 0 (0%) 
SSRI 0 (0%) 0 (0%) 4 (11%) 7 (33%) 
Others 0 (0%) 0 (0%) 2 (5%) 7 (33%) 
Combination 0 (0%) 0 (0%) 10 (26%) 0 (0%) 
NR, Not Recorded; SNRI, Serotonin–norepinephrine reuptake inhibitors; SSRI, Selective serotonin reuptake inhibitors; NaSSa, 651 
Noradrenergic and specific serotonergic antidepressants; TCA, Tricyclic antidepressants; BMI, Body Mass Index; HAMD, Hamilton 652 
Rating Scale for Depression, 17-item-version; #, SNRI (venlafaxine); †, TCA (Imipramine); No*, drug-naive or free for one or six 653 
weeks. 654 
 655 
b) 656 
 
Cohort 5 (n=217) 
Numerical variables (mean|median (SD) [min-max]) 
Age 42|43 (12) [18-64] 
Age of onset 28|25 (13) [5-59] 
BMI (kg/m2) 27|25 (6) [15-53] 
Drinks per week 8|1 (14) [0-66] 
IDS-SR30 score 36|35 (11) [13-63] 
Follow-up IDS-SR30 score 24|23 (13) [1-61] 
Categorical variables 
Follow-up time-point Year 2 
Response (IDS reduction ≥50%) by Year 2  
No 154 (71%) 
Yes 63 (29%) 
Antidepressant medication at baseline  
No 45 (21%) 
Yes 172 (79%) 
Follow-up antidepressant medication by Year 2 
No 0 (0%) 
SSRI 139 (64%) 
Other 40 (18%) 
TCA 15 (7%) 
SNRI 6 (3%) 
NaSSa 3 (1%) 
Combination 14 (6%) 
Gender  
Female 141 (65%) 
Male 76 (35%) 
Sampling frame  
General population 16 (7%) 
Primary care 56 (26%) 
Specialised mental health care 145 (67%) 
Chronic diseases  
21 
 
0 102 (47%) 
1 to 2 106 (49%) 
Over 3 9 (4%) 
MDD Type  
First episode 111 (51%) 
Recurrent 106 (49%) 
Comorbid anxiety diagnosis  
No 64 (29%) 
Yes 153 (71%) 
Somatic medications at baseline  
Anti-inflammatory medication  
No 207 (95%) 
Yes 10 (5%) 
Heart medication  
No 181 (83%) 
Yes 36 (17%) 
Other psychiatric medications at baseline  
Antipsychotics  
No 204 (94%) 
Yes 13 (6%) 
Anxiolytics  
No 185 (85%) 
Yes 32 (15%) 
Benzodiazepines  
No 173 (80%) 
Yes 44 (20%) 
IDS-SR30, Inventory of Depressive Symptoms Self-Report Questionnaire 30-item. 657 
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Table 2. Biomarkers of antidepressant treatment response 685 
Protein Lit Ref Func 
Cohort 1 
(n=30) 
-Venlafaxine- 
Cohort 2 
(n=26) 
-Imipramine- 
Cohort 3 
(n=38) 
-Mixed ADs- 
Cohort 4 
(n=21) 
-Mixed ADs- 
Cohort 5 
(n=217) 
-Mixed ADs- 
 P  P  P  P  P 
B cell-activating factor (BAFF)  IIR -67.89 0.001 11.15 0.499 --- --- --- --- 10.66 0.140 
Thrombomodulin (TM)  BC -41.39 0.012 9.11 0.654 -10.31 0.257 --- --- 6.25 0.417 
Prostasin 
(Bot et 
al., 2015) 
IH -32.01 0.003 -13.18 0.411 --- --- --- --- 3.08 0.514 
Pepsinogen I (PGI)  O -27.00 0.018 11.41 0.267 --- --- --- --- -5.86 0.129 
Apolipoprotein A-IV (ApoA-IV) 
(Bot et 
al., 2015; 
Ejchel et 
al., 2005; 
Zhan et 
al., 2014) 
LM -26.47 0.001 -6.09 0.566 -8.24 0.029 -15.60 0.034* 9.39 0.027 
Endoglin  VR -22.61 0.035 -34.56 0.011 --- --- --- --- 22.89 0.004 
Intercellular Adhesion Molecule 1 (ICAM-1) 
(Dimopo
ulos et 
al., 2006; 
Lesperan
ce et al., 
2004; 
Thomas 
et al., 
2000) 
IIR,CA -21.08 0.035 -24.57 0.097 22.31 0.001 20.37 0.001 1.64 0.799 
Eotaxin-1 
(Domeni
ci et al., 
2010) 
IIR -15.42 0.017 18.02 0.094 3.67 0.231 -4.48 0.118 -4.69 0.142 
Receptor for advanced glycosylation end products (RAGE) 
(Emanue
le et al., 
2011) 
IIR -15.08 0.014 -6.49 0.139 1.08 0.600 -2.61 0.439 -2.27 0.447 
Vascular endothelial growth factor receptor 3 (VEGFR-3)  GFS,AG 21.19 0.005 -4.44 0.634 --- --- --- --- -0.28 0.949 
Interleukin-12 Subunit p40 (IL-12p40) 
(Bot et 
al., 2015; 
Chan et 
al., 
2015a) 
IIR 32.70 0.007 -0.88 0.928 1.93 0.571 --- --- -4.13 0.461 
Peptide YY (PYY) 
(Gimene
z-Palop 
et al., 
2012) 
ES,AR 6.01 0.302 -33.80 0.001 --- --- --- --- --- --- 
Thyroglobulin (TG)  ES,TS -4.62 0.471 -16.19 0.023 --- --- --- --- -3.64 0.167 
Hepatocyte Growth Factor (HGF) 
(Arnold 
et al., 
2012; 
Russo, 
2010) 
GFS,BC 8.67 0.241 -19.84 0.012 14.86 0.024 -3.03 0.497 -1.35 0.742 
Complement C3 (C3) 
(Domeni
ci et al., 
2010) 
IIR,BC 12.11 0.476 -52.06 0.018 -8.02 0.325 15.78 0.024 -0.14 0.985 
Latency-Associated Peptide of Transforming Growth  
Factor beta 1 (LAP TGF-b1) 
 IIR,BC 4.23 0.788 -50.06 0.025 --- --- --- --- -7.71 0.236 
Eosinophil chemotactic protein 2 (Eotaxin-2) 
(Powell 
et al., 
2014) 
IIR 0.69 0.872 -35.20 6.92E-05 --- --- --- --- -3.86 0.146 
Chemokine CC-4 (HCC-4)  IIR 6.34 0.449 -18.56 0.023 1.72 0.649 -0.92 0.780 4.49 0.218 
Kallikrein-7 (KLK-7)  IIR 0.22 0.964 -13.91 0.024 --- --- --- --- --- --- 
Serotransferrin (Transferrin) 
(Baune 
et al., 
2010; 
Maes et 
al., 1992; 
Stelzham
mer et 
al., 2014) 
IH,BC -27.31 0.176 -104.6 3.52E-04 -6.00 0.469 --- --- -10.91 0.258 
Creatine Kinase-MB (CK-MB) 
(Chan et 
al., 
2015a) 
IH -0.86 0.856 -19.57 0.011 -1.05 0.623 2.06 0.539 1.53 0.599 
Mesothelin (MSLN)  O -6.44 0.376 -32.18 0.029 --- --- --- --- 3.38 0.392 
Matrix Metalloproteinase-1 (MMP-1)  BC -2.51 0.597 12.54 0.046 1.43 0.680 --- --- -1.84 0.506 
Lectin-Like Oxidized LDL Receptor 1 (LOX-1)  BC -2.31 0.725 15.28 0.049 -2.12 0.562 --- --- -0.59 0.860 
Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2) 
(Chan et 
al., 
2015a) 
GFS -4.37 0.488 16.07 0.033 4.12 0.170 -6.15 0.027 -2.09 0.514 
Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1)  GFS,AG 0.62 0.908 32.18 0.003 --- --- --- --- --- --- 
Vascular Endothelial Growth Factor C (VEGF-C)  GFS,AG 6.69 0.669 53.20 0.004 --- --- --- --- -10.14 0.199 
Interleukin-1 alpha (IL-1 alpha) 
(Chan et 
al., 
2015a) 
IIR --- --- 20.17 0.042 3.13 0.376 --- --- --- --- 
Interleukin-15 (IL-15)  IIR 9.18 0.219 20.84 0.008 -2.05 0.323 1.38 0.870 --- --- 
CD40 Ligand (CD40-L) 
(Neubau
er et al., 
2013) 
IIR 3.51 0.531 21.89 0.039 5.05 0.059 -4.74 0.077 1.30 0.565 
Resistin 
(Carvalh
o et al., 
2014; 
Papakost
as et al., 
2013) 
IIR,ES 0.14 0.991 33.90 0.041 4.36 0.322 1.14 0.712 -0.04 0.993 
Osteoprotegerin (OPG)  IIR -4.57 0.745 39.80 0.010 --- --- --- --- -8.93 0.138 
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B Lymphocyte Chemoattractant (BLC)  IIR 5.78 0.491 50.45 0.010 0.66 0.844 -0.89 0.620 --- --- 
Tamm-Horsfall Urinary Glycoprotein (THP)  IH 3.69 0.697 68.23 1.15E-04 -0.88 0.780 --- --- -0.34 0.942 
Apolipoprotein E (Apo E)  LM -5.51 0.515 36.06 0.011 -0.35 0.935 --- --- 4.97 0.110 
Fetuin-A 
(Bot et 
al., 2015) 
IIR -16.20 0.281 5.27 0.758 -15.82 0.016 --- --- 0.57 0.930 
CD5 Antigen-like (CD5L)  IIR 5.77 0.599 -6.95 0.638 -12.63 0.045 --- --- -5.65 0.227 
Alpha-2-Macroglobulin (A2Macro) 
(Chan et 
al., 
2015a; 
Ditzen et 
al., 2012; 
Domenic
i et al., 
2010; 
Rotherm
undt et 
al., 2001; 
Seidel et 
al., 1995) 
IIR,BC 6.89 0.693 10.58 0.762 -12.20 0.016 8.52 0.207 -7.16 0.159 
Plasminogen Activator Inhibitor 1 (PAI-1) 
(Eskanda
ri et al., 
2005; 
Gorska-
Ciebiada 
et al., 
2016; 
Tsai et 
al., 2008) 
BC,AG 11.40 0.385 31.99 0.063 14.60 0.025 20.92 0.001 -2.42 0.665 
Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) 
(Domeni
ci et al., 
2010) 
BC 26.21 0.246 -5.21 0.810 15.07 0.043 25.50 0.017 -14.11 0.097 
Thrombopoietin (TPO)  BC 5.30 0.676 15.30 0.673 19.77 0.009 14.39 0.048 --- --- 
Cortisol 
(Chan et 
al., 
2015a; 
Cubala 
and 
Landows
ki, 2014; 
Karlovic 
et al., 
2012; 
Maes et 
al., 1997; 
Owens 
et al., 
2014; 
Papakost
as et al., 
2013; 
Rheberg
en et al., 
2015; 
Simic et 
al., 2013; 
Stetler 
and 
Miller, 
2011; 
Wong et 
al., 2000) 
ES,HPA 9.06 0.168 3.23 0.555 6.72 0.002 3.08 0.459 -2.70 0.478 
Vascular Endothelial Growth Factor (VEGF) 
(Arnold 
et al., 
2012; 
Bot et 
al., 2015) 
GFS,AG 9.82 0.248 1.16 0.906 9.31 0.035 0.77 0.877 -0.67 0.872 
Tenascin-C (TN-C) 
(Bot et 
al., 2015; 
Stelzham
mer et 
al., 2014) 
GFS -2.30 0.754 6.96 0.566 11.35 0.002 3.63 0.294 -8.48 0.128 
Stem Cell Factor (SCF)  GFS 6.07 0.572 -3.33 0.855 12.94 0.004 1.26 0.905 6.90 0.372 
Haptoglobin 
(Karaoul
anis et 
al., 2014) 
IIR 8.19 0.193 5.47 0.461 7.26 0.005 1.99 0.472 0.98 0.711 
Interleukin-1 receptor antagonist (IL-1ra) 
(Bot et 
al., 2015; 
Chan et 
al., 
2015a; 
Kaestner 
et al., 
2005; 
Lehto et 
al., 2010; 
Stelzham
mer et 
al., 2014) 
IIR -1.31 0.809 18.05 0.084 8.48 0.036 3.68 0.196 0.61 0.921 
FASLG Receptor (FAS)  IIR 13.09 0.339 -17.45 0.084 12.21 0.033 -6.27 0.305 6.90 0.073 
Carcinoembryonic Antigen (CEA) 
(Bot et 
al., 2015) 
O -5.41 0.336 -13.81 0.153 3.09 0.036 0.06 0.972 1.43 0.573 
Prostatic Acid Phosphatase (PAP)  O -19.35 0.051 -4.98 0.662 9.43 0.025 3.51 0.588 --- --- 
Cystatin-C 
(Bot et 
al., 2015) 
O 18.80 0.223 6.13 0.760 24.14 0.033 --- --- -9.25 0.344 
Progesterone 
(Abou-
Saleh et 
al., 1998) 
ES -9.99 0.365 -2.26 0.870 4.16 0.130 -13.17 1.84E-04 3.44 0.462 
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Betacellulin (BTC) 
(Lu et al., 
2013) 
GFS --- --- --- --- -0.84 0.877 -15.91 0.009 --- --- 
Insulin-like Growth Factor I (IGF-I) 
(Deuschl
e et al., 
1997; 
Weber-
Hamann 
et al., 
2009) 
GFS,BC --- --- --- --- -3.05 0.160 -2.39 0.040 --- --- 
Interleukin-4 (IL-4) 
(Domeni
ci et al., 
2010; 
Simon et 
al., 2008) 
IIR --- --- --- --- --- --- -13.31 0.046 --- --- 
Eotaxin-3  IIR --- --- --- --- --- --- -7.34 0.009 --- --- 
Interleukin-13 (IL-13) 
(Chan et 
al., 
2015a; 
Simon et 
al., 2008) 
IIR -4.14 0.487 11.92 0.289 1.51 0.792 -6.33 0.019 --- --- 
Alpha-Fetoprotein (AFP)  O 3.28 0.482 -6.67 0.322 1.63 0.376 -7.47 0.034 --- --- 
Angiotensin-Converting Enzyme (ACE) 
(Chan et 
al., 
2015a; 
Kaestner 
et al., 
2005; 
Stelzham
mer et 
al., 2014) 
VR -0.09 0.992 12.68 0.189 -7.97 0.228 -9.36 0.015 -0.47 0.932 
Thrombospondin-1 (TSP-1)  BC -40.25 0.095 54.70 0.073 2.41 0.466 23.49 0.005 -0.73 0.864 
Insulin 
(Arnold 
et al., 
2012; 
Chan et 
al., 
2015a; 
Domenic
i et al., 
2010; 
Okamura 
et al., 
2000) 
CM -4.63 0.366 -0.74 0.939 1.28 0.626 3.42 0.008 1.99 0.314 
Thyroxine-Binding Globulin (TBG) 
(Chan et 
al., 
2015a) 
ES,TS -1.52 0.948 -3.39 0.886 -10.18 0.084 16.46 0.019 -5.68 0.411 
C-Reactive Protein (CRP) 
(Domeni
ci et al., 
2010) 
IIR 3.29 0.113 1.73 0.478 1.63 0.118 2.97 0.023 -1.65 0.211 
EN-RAGE 
(Bot et 
al., 2015; 
Chan et 
al., 
2015a; 
Kaestner 
et al., 
2005; 
Stelzham
mer et 
al., 2014) 
IIR -2.09 0.543 2.11 0.734 1.08 0.620 7.61 0.005 -0.25 0.909 
Myeloperoxidase (MPO) 
(Papakos
tas et al., 
2013) 
IIR -1.01 0.788 15.17 0.105 2.09 0.521 10.99 0.011 0.66 0.764 
Serum Amyloid P-Component (SAP) 
(Domeni
ci et al., 
2010) 
IIR 3.52 0.631 0.71 0.967 -1.26 0.849 13.22 0.005 1.59 0.777 
Apolipoprotein(a) (Lp(a)) 
(Domeni
ci et al., 
2010) 
LM 2.14 0.402 5.43 0.226 1.26 0.339 2.65 0.049 -0.01 0.995 
Matrix Metalloproteinase-10 (MMP-10) 
(Bot et 
al., 2015) 
O -19.53 0.050 -4.88 0.747 3.74 0.253 --- --- 10.35 0.013 
Collagen IV  O -0.52 0.947 9.62 0.314 --- --- --- --- -7.87 0.023 
Glucose-6-phosphate Isomerase (G6PI)  CM,AG --- --- --- --- --- --- --- --- -8.55 0.039 
Insulin-like Growth Factor-Binding Protein 1 (IGFBP-1)  GFS -2.03 0.546 1.92 0.769 --- --- --- --- -3.29 0.018 
Beta-2-Microglobulin (B2M) 
(Domeni
ci et al., 
2010) 
IIR 22.90 0.079 0.70 0.967 6.94 0.344 17.18 0.107 -14.41 0.014 
Immunoglobulin A (IgA) 
(Gold et 
al., 2012) 
IIR -5.44 0.401 2.77 0.724 5.18 0.295 0.03 0.994 -7.41 0.039 
Immunoglobulin M (IgM) 
(Domeni
ci et al., 
2010) 
IIR -7.53 0.172 -2.26 0.743 -2.83 0.210 4.23 0.218 -9.80 0.003 
Monocyte Chemotactic Protein 1 (MCP-1) 
(Bai et 
al., 2014; 
Chan et 
al., 
2015a; 
Simon et 
al., 2008) 
IIR,AG -3.19 0.730 12.05 0.471 3.45 0.513 6.58 0.237 -12.92 0.003 
Platelet-Derived Growth Factor BB (PDGF-BB)  GFS,AG 6.79 0.466 33.70 0.056 5.67 0.254 -4.41 0.618 -8.84 0.029 
Prolactin (PRL)  ES 11.73 0.126 15.11 0.050 1.81 0.443 -3.05 0.086 -7.95 0.020 
, Regression Coefficient Estimates; P, P-value; Lit Ref, Literature References; ADs, Antidepressants; Func, Biological Function; AG, 686 
Angiogenesis; AR, Appetite Regulation; BC, Blood Coagulation; CM, Carbohydrate Metabolism; CA, Cell Adhesion; ES, Endocrine 687 
Signalling; GFS, Growth Factor Signalling; HPA, Hypothalamic–Pituitary–Adrenal Axis Signalling; IIR, Immune/Inflammatory 688 
Response; IH, Ion Homeostasis; LM, Lipid Metabolism; O, Other; TS, Thyroid Signalling; VR, Vascular Regulation. *, LC-MS data as 689 
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this protein was not measured by the RBM platform in cohort 4. See Supplementary Table 1 for the full list of proteins measured 690 
across each cohort. 691 
 692 
 693 
 694 
 695 
 696 
Figure legends 697 
 698 
Figure 1. Polar histogram showing the biomarkers of treatment response identified across the five 699 
independent cohorts.  700 
Key: Direction of association = direction of regression coefficient estimates, which can be positive ( or negative (-701 
 Positive () = higher baseline protein level is associated with better response to treatment; Negative (-) =lower 702 
baseline protein level is associated with better response to treatment; Not significant = P<0.05; Not measured = not 703 
measured by DiscMAP version used to profile samples in the respective cohort. 704 
 705 
 706 
 707 
Supplementary Figure 1. Association between treatment response and baseline APOA-IV levels in cohorts 708 
1, 3, 4 and 5.  709 
 710 
